Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8786012 | Clinical Oncology | 2018 | 8 Pages |
Abstract
In the present study, etPET/CT revealed metabolically active lesions in complete responders after EOC primary therapy, but they were insignificant for the patient's prognosis. The current study does not favour routine use of 18F-FDG PET/CT after EOC primary treatment for complete responders.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
J. Hynninen, M. Laasik, T. Vallius, J. Kemppainen, S. Grönroos, J. Virtanen, J. Casado, S. Hautaniemi, S. Grenman, M. Seppänen, A. Auranen,